MedPath

FDA Clears Philips Spectral 4DCT for Enhanced Precision in Radiation Oncology

• The FDA has granted 510(k) clearance to Philips Spectral CT 7500 RT, a spectral 4DCT respiratory-gated imaging solution for radiation oncology. • Spectral CT 7500 RT enhances accuracy in cancer treatment planning, minimizing damage to healthy tissue and potential adverse effects. • The technology integrates conventional and spectral CT capabilities, offering improved tissue characterization and personalized treatment planning. • Studies show Spectral CT 7500 RT significantly reduces proton stopping-power ratio error, improving radiation dose calculation accuracy.

Philips Spectral CT 7500 RT has received FDA 510(k) clearance, marking a significant advancement in radiation oncology. This detector-based spectral CT radiotherapy solution allows radiation oncologists to precisely target radiation therapy based on a patient's specific tumor physiology.

Precision in Radiation Therapy

Spectral CT 7500 RT is designed to enhance the accuracy of cancer treatment planning while minimizing damage to surrounding healthy tissue. The technology aims to reduce potential adverse effects in patients undergoing radiation therapy by integrating conventional and spectral CT capabilities into a single scan. This integration makes it compatible with existing clinical workflows and offers respiratory-gated spectral imaging, enabling oncologists to leverage the benefits of 4D conventional CT along with the enhanced visualization and quantification provided by spectral CT.

Improved Accuracy and Efficiency

According to Philips, the Spectral CT 7500 RT significantly reduces proton stopping-power ratio (SPR) error by more than 50% compared to conventional CT. This reduction leads to improved accuracy in radiation dose calculation, minimizing exposure to healthy tissues and enhancing the precision of cancer treatments. The system can automatically generate SPR maps and direct electron density (ED) results, achieving deviations of less than 1%, which aids oncologists in optimizing radiotherapy planning and ensuring accurate dose delivery.

Expert Insights

"The Spectral CT system provides us with several capabilities that conventional CT does not have. It can provide electron density and effective atomic number results, which we can convert to the proton stopping-power ratio. And published data shows that the stopping power ratio obtained in this way has fewer uncertainties compared to regular calibration curves, thereby reducing the uncertainty margins during treatment planning," said Zhong Su, PhD, Physics Director, Department of Radiation Oncology at the University of Arkansas for Medical Sciences Medical Center.

Clinical Impact

The Spectral CT 7500 RT offers improved accuracy, cost-effectiveness, and workflow efficiency by seamlessly integrating with existing protocols. Dan Xu, global business leader of CT at Philips, noted, "Tumor delineation, beam attenuation, and respiratory motion are critical factors in radiotherapy planning. The spectral information provided by Spectral CT 7500 RT enhances tissue characterization, enabling wider access to highly personalized and precisely targeted treatment for more patients without adding extra steps to current radiotherapy workflows."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CRISPR Therapeutics' CTX112 Shows Promise in B-Cell Malignancies, Receives FDA RMAT Designation

CRISPR Therapeutics presented encouraging Phase 1/2 data for CTX112, an allogeneic CAR T-cell therapy, at the ASH Annual Meeting.
CTX112 demonstrated potential clinical benefit with a manageable safety profile in patients with relapsed or refractory CD19-positive B-cell malignancies.

SyntheticMR's SyMRI 15 Receives FDA 510(k) Clearance for Diagnostic Image Replacement

SyntheticMR's SyMRI 15 has received FDA 510(k) clearance, enabling its use for diagnostic image replacement of conventional MRI images.
The technology enhances MRI workflows by replacing conventional 3D imaging and providing tissue quantification.

Nanox's ARC Imaging System Receives FDA Clearance for Expanded Use

Nanox's ARC imaging system secures FDA 510(k) clearance for general use, including pulmonary, intra-abdominal, and paranasal sinus indications, expanding its market potential.
The Nanox.ARC system utilizes digital X-ray technology with cold cathode tomosynthesis, providing enhanced 3D visualization compared to traditional 2D X-rays.

FDA Clears Philips' ROCC for Remote Radiology Operations

Philips secures FDA 510(k) clearance for its Radiology Operations Command Center (ROCC), enhancing remote scanning and protocol management capabilities.
The ROCC system, compatible with various MR and CT systems, connects imaging experts with technologists across different locations.

Acuitive Technologies' CITREPORE Receives FDA Clearance as Novel Bone Void Filler

Acuitive Technologies secured FDA 510(k) clearance for CITREPORE, a synthetic bioactive bone void filler utilizing CITREGEN® technology, designed for orthopedic procedures.
CITREPORE is engineered to resorb predictably, facilitating bone regeneration by releasing citrate, which enhances bone metabolism and formation during the healing process.

iCAD's ProFound Detection 4.0 Receives FDA Clearance for Enhanced Breast Cancer Detection

iCAD's ProFound Detection Version 4.0, an AI-powered solution for digital breast tomosynthesis, has received FDA clearance, enhancing cancer detection and specificity.
The new version demonstrates a 6.3% improvement in AUC, leading to better identification of aggressive cancers and a reduction in false positives.

FDA Clears Gentuity's HF-OCT Imaging System for Coronary Interventions

Gentuity receives FDA 510(k) clearance for its HF-OCT imaging system with the Vis-Rx micro-imaging catheter, enhancing coronary intervention procedures.
The system is the only intravascular imaging platform indicated for pre- and post- percutaneous coronary intervention (PCI) assessment, optimizing treatment plans.

SPECTRALIS Flex Module Receives FDA Clearance, Expanding Ophthalmic Imaging Access

Heidelberg Engineering's SPECTRALIS Flex Module received FDA clearance, offering multimodal ophthalmic imaging for pediatric and adult patients in a supine position.
The Flex Module adapts the SPECTRALIS technology to a movable stand, enhancing accessibility for patients unable to use traditional tabletop OCT devices.

FDA Approves Illumina's TruSight Oncology Comprehensive Assay as Pan-Tumor Companion Diagnostic

The FDA has approved Illumina's TruSight Oncology (TSO) Comprehensive Assay as a pan-tumor companion diagnostic, enhancing precision medicine.
TSO Comprehensive is the first FDA-approved kit for identifying NTRK-positive solid tumor patients eligible for larotrectinib and RET fusion-positive NSCLC patients for selpercatinib.

FDA's July Roundup: Approvals, Fast Tracks, and Designations in Oncology

The FDA approved FoundationOne Liquid CDx as a companion diagnostic for niraparib and abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer.
Several therapies received fast track designations, including OBX-115 for advanced melanoma and ADI-270 for metastatic clear cell renal cell carcinoma.

Reference News

[1]
FDA Clears Spectral 4DCT for Precision in Radiation Oncology
targetedonc.com · Nov 18, 2024

The FDA granted 510(k) clearance to Philips Spectral CT 7500 RT, a spectral 4DCT respiratory-gated imaging system for ra...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy